Guardant Health (NASDAQ:GH) Director Sells $11,131.36 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $95.96, for a total value of $11,131.36. Following the sale, the director owned 8,662 shares of the company’s stock, valued at approximately $831,205.52. This trade represents a 1.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $84.83, for a total value of $9,840.28.
• On Wednesday, March 18th, Musa Tariq sold 348 shares of Guardant Health stock. The shares were sold at an average price of $88.09, for a total value of $30,655.32.

Guardant Health Stock Up 2.6%

Shares of NASDAQ GH opened at $118.01 on Friday. Guardant Health, Inc. has a fifty-two week low of $36.36 and a fifty-two week high of $121.01. The business has a 50 day moving average price of $90.53 and a two-hundred day moving average price of $98.79. The firm has a market cap of $15.65 billion, a PE ratio of -34.81 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to the consensus estimate of $269.74 million. The company’s quarterly revenue was up 39.4% on a year-over-year basis. During the same period last year, the firm posted ($0.62) EPS. On average, analysts anticipate that Guardant Health, Inc. will post -2.92 earnings per share for the current year.

Analysts Set New Price Targets

GH has been the subject of several research reports. JPMorgan Chase & Co. lifted their target price on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Wells Fargo & Company lifted their target price on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Raymond James Financial restated an “outperform” rating and set a $129.00 price objective on shares of Guardant Health in a research report on Monday, February 23rd. Leerink Partners boosted their price objective on Guardant Health from $170.00 to $180.00 and gave the company an “outperform” rating in a research report on Friday, February 20th. Finally, Evercore set a $110.00 price objective on Guardant Health in a research report on Friday, February 20th. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and a consensus target price of $129.00.

Institutional Trading of Guardant Health

Hedge funds have recently added to or reduced their stakes in the business. Emerald Advisers LLC raised its stake in Guardant Health by 24.8% during the 3rd quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock valued at $54,558,000 after acquiring an additional 173,281 shares in the last quarter. Knights of Columbus Asset Advisors LLC bought a new stake in Guardant Health during the 3rd quarter valued at $1,554,000. Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Guardant Health by 54.4% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock valued at $18,835,000 after acquiring an additional 106,263 shares in the last quarter. Erste Asset Management GmbH raised its stake in Guardant Health by 10.4% during the 3rd quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after acquiring an additional 66,617 shares in the last quarter. Finally, Segall Bryant & Hamill LLC raised its stake in Guardant Health by 57.8% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after acquiring an additional 111,822 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.